Journal article
Buprenorphine transdermal system in adults with chronic low back pain: A randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase
Abstract
BACKGROUND: Buprenorphine is a mixed-activity, partial mu-opioid agonist. Its lipid solubility makes it well suited for transdermal administration.
OBJECTIVE: This study assessed the efficacy and safety profile of a 7-day buprenorphine transdermal system (BTDS) in adult (age >18 years) patients with moderate to severe chronic low back pain previously treated with > or =1 tablet daily of an opioid analgesic.
Authors
Gordon A; Callaghan D; Spink D; Cloutier C; Dzongowski P; O’Mahony W; Sinclair D; Rashiq S; Buckley N; Cohen G
Journal
Clinical Therapeutics, Vol. 32, No. 5, pp. 844–860
Publisher
Elsevier
Publication Date
May 2010
DOI
10.1016/j.clinthera.2010.04.018
ISSN
0149-2918